OBJECTIVE: We assessed the impact of a sustained virological response (SVR) on liver stiffness among HIV/hepatitis C virus (HCV)-coinfected patients enrolled in the ANRS CO13 HEPAVIH cohort. METHODS: We studied HIV/HCV-coinfected patients who received at least one dose of any anti-HCV treatment and who had documented SVR status, a pretreatment FibroScan value of at least 7.1 kPa, and at least one posttreatment FibroScan value. The time required to achieve at least a 30% decrease in liver stiffness was analyzed by constructing Kaplan-Meier curves and using Cox proportional hazards models. RESULTS: Among 98 patients treated for HCV infection with either pegylated interferon along with ribavirin (n = 89) or protease inhibitor-based triple therapy (n = 9), 53 patients (54%) had an SVR. Median follow-up was 44.6 (interquartile range: 28.8-58.9) months. The probability of achieving a 30% decrease in FibroScan values was 51% [95% confidence interval (CI): 39-66] in patients with an SVR and 21% in nonresponders (95% CI: 11-36) at 1 year, and 74% (61-86) and 28% (17-44) at 2 years, respectively. In the subgroup of 35 cirrhotic patients (pretreatment liver stiffness ≥12.5 kPa), 14 of 18 patients with an SVR and three of 17 nonresponders had a fibrosis score below 12.5 kPa at the last follow-up examination. Multivariable analysis showed that SVR was independently associated with a ≥30% reduction in liver stiffness, both in the overall study group (hazard ratio: 5.77; 95% CI: 2.00-16.62; P = 0.0012) and in cirrhotic patients (hazard ratio: 8.21; 95% CI: 2.15-31.34; P = 0.0021). Robustness analyses using FIB4 values showed similar results. CONCLUSION: SVR is significantly associated with improvement in liver stiffness in HIV/HCV-coinfected patients, including those with cirrhosis.
OBJECTIVE: We assessed the impact of a sustained virological response (SVR) on liver stiffness among HIV/hepatitis C virus (HCV)-coinfectedpatients enrolled in the ANRS CO13 HEPAVIH cohort. METHODS: We studied HIV/HCV-coinfectedpatients who received at least one dose of any anti-HCV treatment and who had documented SVR status, a pretreatment FibroScan value of at least 7.1 kPa, and at least one posttreatment FibroScan value. The time required to achieve at least a 30% decrease in liver stiffness was analyzed by constructing Kaplan-Meier curves and using Cox proportional hazards models. RESULTS: Among 98 patients treated for HCV infection with either pegylated interferon along with ribavirin (n = 89) or protease inhibitor-based triple therapy (n = 9), 53 patients (54%) had an SVR. Median follow-up was 44.6 (interquartile range: 28.8-58.9) months. The probability of achieving a 30% decrease in FibroScan values was 51% [95% confidence interval (CI): 39-66] in patients with an SVR and 21% in nonresponders (95% CI: 11-36) at 1 year, and 74% (61-86) and 28% (17-44) at 2 years, respectively. In the subgroup of 35 cirrhotic patients (pretreatment liver stiffness ≥12.5 kPa), 14 of 18 patients with an SVR and three of 17 nonresponders had a fibrosis score below 12.5 kPa at the last follow-up examination. Multivariable analysis showed that SVR was independently associated with a ≥30% reduction in liver stiffness, both in the overall study group (hazard ratio: 5.77; 95% CI: 2.00-16.62; P = 0.0012) and in cirrhotic patients (hazard ratio: 8.21; 95% CI: 2.15-31.34; P = 0.0021). Robustness analyses using FIB4 values showed similar results. CONCLUSION: SVR is significantly associated with improvement in liver stiffness in HIV/HCV-coinfectedpatients, including those with cirrhosis.
Authors: Mattias Mandorfer; Philipp Schwabl; Sebastian Steiner; Thomas Reiberger; Markus Peck-Radosavljevic Journal: Hepatol Int Date: 2016-01-12 Impact factor: 6.047
Authors: Julia B Balmaceda; Julia Aepfelbacher; Olivia Belliveau; Chloe S Chaudhury; Cheryl Chairez; Mary McLaughlin; Rachel Silk; Chloe Gross; Sarah Kattakuzhy; Elana Rosenthal; Shyam Kottilil; David E Kleiner; Colleen Hadigan Journal: Antivir Ther Date: 2019
Authors: Mei Lu; Jia Li; Talan Zhang; Loralee B Rupp; Sheri Trudeau; Scott D Holmberg; Anne C Moorman; Philip R Spradling; Eyasu H Teshale; Fujie Xu; Joseph A Boscarino; Mark A Schmidt; Vinutha Vijayadeva; Stuart C Gordon Journal: Clin Gastroenterol Hepatol Date: 2016-01-22 Impact factor: 11.382
Authors: Sebastian Steiner; Theresa Bucsics; Philipp Schwabl; Mattias Mandorfer; Bernhard Scheiner; Maximilian Christopher Aichelburg; Katharina Grabmeier-Pfistershammer; Peter Ferenci; Michael Trauner; Markus Peck-Radosavljevic; Thomas Reiberger Journal: Wien Klin Wochenschr Date: 2017-01-27 Impact factor: 1.704
Authors: Sweta Chekuri; Jillian Nickerson; Kian Bichoupan; Roberta Sefcik; Kamini Doobay; Sanders Chang; David DelBello; Alyson Harty; Douglas T Dieterich; Ponni V Perumalswami; Andrea D Branch Journal: PLoS One Date: 2016-07-21 Impact factor: 3.240